A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and

A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi
    SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.

PR Newswire

NEW YORK, February 21, 2013

NEW YORK, February 21, 2013 /PRNewswire/ --

Today, National Traders Association announced new research reports
highlighting Novogen Limited (NASDAQ: NVGN), Sanofi SA (NYSE: SNY), ISIS
Pharmaceuticals, Inc. (NASDAQ: ISIS), Amgen, Inc. (NASDAQ: AMGN) and Gilead
Sciences, Inc. (NASDAQ: GILD). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Novogen Limited Research Report

Novogen's shares jumped 200 percent after a study revealed that its
anti-ovarian cancer drug was not only effective against ovarian cancer cells,
it was also effective against ovarian cancer stem cells. Cancer stem cells
have been found in a range of cancers including ovarian, brain and leukemia,
and are resistant to radiotherapy and typical anti-cancer drugs. They are also
normally responsible for cancer recurrence, the main cause of death among
patients. With this new discovery, Novogen hopes that its new drug, the CS-6
and the super benzopyran family of drugs to which it belongs, would eventually
become a comprehensive cancer treatment. Many investors have already jumped to
buy shares, expecting that CS-6 would become the catalyst for Novogen's
long-term growth. The Full Research Report on Novogen Limited - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.NationalTradersAssociation.org/r/full_research_report/0f8c_NVGN]

--

Sanofi SA Research Report

Sanofi's shares rallied after the U.S. Food and Drug Administration (FDA)
accepted lixisenatide for review. Lixisenatide is the first once-daily
treatment of adults with type 2 diabetes mellitus. Lixisenatide has also been
approved for the European Union, and will be launched as Lyxumia later in the
first quarter. This follows regulatory approvals for Kynamro, Zaltrap, and
Aubagio. Additionally, Sanofi's subsidiary Genzyme also announced positive new
data from phase 3 ENGAGE and ENCORE studies of eliglustat tartrate, an
investigational oral therapy for Gaucher disease type 1. With a string of
approvals to boast of, many believe that the pharmaceutical giant will be able
to generate strong revenue in the upcoming quarters. Warren Buffett is among
Sanofi's shareholders, along with Abrams Capital. The Full Research Report on
Sanofi SA - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.NationalTradersAssociation.org/r/full_research_report/63b2_SNY]

--

ISIS Pharmaceuticals, Inc. Research Report

ISIS and Genzyme have announced the US Food and Drug Administration (FDA)
approval of their new product, the KYNAMROTM injection. The injection reduces
low density liproprotein-cholesterol, apoliprotein B, total cholesterol, and
high density lipoprotein-cholesterol in patients with homozygous familial
hypercholesterolemia (HoFH). HoFH is a rare inherited condition which makes
the body unable to remove LDL cholesterol. In the United States, HoFH occurs
in one in a million individuals, and for patients with this condition, heart
attacks, and death can occur before age 30. Analysts expect that the product
will earn $400 million in peak sales, with Isis getting 30 percent to 50
percent of the profit, depending on total sales. Sanofi, the pharma giant that
owns Genzyme, will be helping to market this product. Moreover, ISIS recently
earned $7.5 million payment from GlaxoSmithKline for the initiation of the
Phase2/3 clinical study of ISIS-TTR, a treatment for transthyretin (TTR)
amyloidosis, a genetic disease characterized by the dysfunction of peripheral
nerve or heart tissues. The Full Research Report on ISIS Pharmaceuticals, Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.NationalTradersAssociation.org/r/full_research_report/555f_ISIS]

--

Amgen, Inc. Research Report

Amgen reported that its late-stage pipeline is advancing, with two pivotal
phase 3 trials due this year, five in 2014, and one in 2016. Analysts have
been praising Amgen for its promising pipeline and its solid long-term
strategy, with researchers at the Jefferies Group reiterating their buy rating
on the shares of the company. The world's largest biotechnology company notes
six biosimilars as its next opportunity for growth, hoping that these products
would generate a combined peak of $41 billion in global sales. It is also
creating a new manufacturing process that includes launching new manufacturing
technologies that aim to reduce the capital needed to produce products. It is
also planning to expand globally as it launches products in Japan by 2016. The
Full Research Report on Amgen, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:
[http://www.NationalTradersAssociation.org/r/full_research_report/7b3e_AMGN]

--

Gilead Sciences, Inc. Research Report

Gilead announced results from the Phase 3 FUSION study of its Hepatitis C
drug, Sofosbuvir. The study concluded that the drug is effective in treating
Hepatitis C patients who could not be cured by existing medications that
contained pegylated interferon. Interferon is an ingredient loaded with side
effects that often led to patients discontinuing therapy. With this, Gilead is
on track to file regulatory applications for the drug in the United States and
Europe in the second quarter. The results mark a remarkable run for the
company after taking less than 16 months to finish its Phase III phase. The
Full Research Report on Gilead Sciences, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
[http://www.NationalTradersAssociation.org/r/full_research_report/6e69_GILD]

--

Consider National Traders Association

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Demi Lapierre
Email: press@NationalTradersAssociation.org
Main: +1(702)212-4493

SOURCE National Traders Association
 
Press spacebar to pause and continue. Press esc to stop.